سعر صانيكارديو 12.5مجم/50 مل محلول وريدي 2022

Sunnycardio tirofiban 12.5 mg/50 mL for intravenous infusion, single 50 mL unit (Sunny Medical, Egypt); glycoprotein IIb/IIIa receptor antagonist antiplatelet.

• Prevention of early myocardial infarction in adults with non-ST-elevation acute coronary syndrome (last chest pain within 12 hours, with ECG changes and/or elevated cardiac enzymes).electronic medicines compendium (emc)
• Reduction of major cardiovascular events in acute myocardial infarction (STEMI) intended for primary PCI.electronic medicines compendium (emc)

• Bleeding is the most common adverse reaction (usually mild mucocutaneous or catheter-site); gastrointestinal, retroperitoneal, intracranial and pulmonary haemorrhage reported; the most serious reaction was fatal bleeding.International label, same formulation · electronic medicines compendium (emc)

• Hypersensitivity to tirofiban or excipients, or thrombocytopenia during earlier GP IIb/IIIa antagonist use.International label, same formulation · electronic medicines compendium (emc)
• Stroke within 30 days or any history of haemorrhagic stroke; known intracranial disease (neoplasm, arteriovenous malformation, aneurysm).International label, same formulation · electronic medicines compendium (emc)
• Active or recent (within 30 days) clinically relevant bleeding; malignant hypertension; relevant trauma or major surgery within 6 weeks.International label, same formulation · electronic medicines compendium (emc)

• Use without unfractionated heparin is not recommended; not recommended with thrombolytic therapy; stop immediately if thrombolysis, emergency CABG or intra-aortic balloon pump is needed.International label, same formulation · electronic medicines compendium (emc)
• Bleeding risk: monitor carefully for bleeding; higher risk in elderly, female and low-body-weight patients and with reduced creatinine clearance (<60 mL/min); minimise vascular punctures and IM injections; care at femoral sheath site.International label, same formulation · electronic medicines compendium (emc)
• Contains approximately 189 mg sodium per 50 mL vial (UK concentrate).International label, same formulation · electronic medicines compendium (emc)

• Other platelet aggregation inhibitors, heparin, warfarin, thrombolyticsCombined use increases bleeding risk; concomitant warfarin with tirofiban plus heparin increased bleeding; not recommended with thrombolytics or other drugs that relevantly increase bleeding risk (oral anticoagulants, other parenteral GP IIb/IIIa inhibitors, dextran).electronic medicines compendium (emc)
• EnoxaparinLimited experience; higher frequency of cutaneous and oral bleeding than with unfractionated heparin.electronic medicines compendium (emc)

• No or limited data in pregnant women; not recommended during pregnancy unless clearly necessary.International label, same formulation · electronic medicines compendium (emc)
• Unknown whether excreted in human milk (excreted in animal milk); decide whether to stop breastfeeding or therapy.International label, same formulation · electronic medicines compendium (emc)

• Tirofiban: Reversible antagonist of fibrinogen binding to the platelet GP IIb/IIIa receptor, inhibiting platelet aggregation (US AGGRASTAT label).